56056-25-8 Usage
Description
1-(4-Bromo-2-Methylphenyl)hydrazine, HCl is a hydrazine derivative featuring a 4-bromo-2-methylphenyl group and a hydrochloric acid molecule. This chemical compound is utilized in organic synthesis and pharmaceutical research, serving as a fundamental building block for creating a variety of organic compounds. Its potential extends to the development of new drugs, agrochemicals, and materials. Due to the toxic and hazardous nature of hydrazine compounds, careful handling and storage are essential.
Uses
Used in Pharmaceutical Research:
1-(4-Bromo-2-Methylphenyl)hydrazine, HCl is used as a building block for the development of new pharmaceutical compounds. Its unique structure allows for the creation of diverse organic molecules with potential therapeutic applications.
Used in Agrochemical Development:
In the agrochemical industry, 1-(4-Bromo-2-Methylphenyl)hydrazine, HCl is used as a starting material for the synthesis of various agrochemicals, contributing to the development of new pesticides and other agricultural products.
Used in Material Science:
1-(4-Bromo-2-Methylphenyl)hydrazine, HCl is employed as a component in the development of new materials, leveraging its chemical properties to create innovative substances with unique characteristics and potential applications in various industries.
Check Digit Verification of cas no
The CAS Registry Mumber 56056-25-8 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 5,6,0,5 and 6 respectively; the second part has 2 digits, 2 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 56056-25:
(7*5)+(6*6)+(5*0)+(4*5)+(3*6)+(2*2)+(1*5)=118
118 % 10 = 8
So 56056-25-8 is a valid CAS Registry Number.
56056-25-8Relevant articles and documents
Maximizing lipophilic efficiency: The use of Free-Wilson analysis in the design of inhibitors of acetyl-CoA carboxylase
Freeman-Cook, Kevin D.,Amor, Paul,Bader, Scott,Buzon, Leanne M.,Coffey, Steven B.,Corbett, Jeffrey W.,Dirico, Kenneth J.,Doran, Shawn D.,Elliott, Richard L.,Esler, William,Guzman-Perez, Angel,Henegar, Kevin E.,Houser, Janet A.,Jones, Christopher S.,Limberakis, Chris,Loomis, Katherine,McPherson, Kirk,Murdande, Sharad,Nelson, Kendra L.,Phillion, Dennis,Pierce, Betsy S.,Song, Wei,Sugarman, Eliot,Tapley, Susan,Tu, Meihua,Zhao, Zhengrong
supporting information; experimental part, p. 935 - 942 (2012/03/11)
This paper describes the design and synthesis of a novel series of dual inhibitors of acetyl-CoA carboxylase 1 and 2 (ACC1 and ACC2). Key findings include the discovery of an initial lead that was modestly potent and subsequent medicinal chemistry optimization with a focus on lipophilic efficiency (LipE) to balance overall druglike properties. Free-Wilson methodology provided a clear breakdown of the contributions of specific structural elements to the overall LipE, a rationale for prioritization of virtual compounds for synthesis, and a highly successful prediction of the LipE of the resulting analogues. Further preclinical assays, including in vivo malonyl-CoA reduction in both rat liver (ACC1) and rat muscle (ACC2), identified an advanced analogue that progressed to regulatory toxicity studies.
